Key result
Elevated sST2 linked to ~7% increased risk of incident AF and post-ablation recurrence.
Why the study?
The role of soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation development and recurrence after catheter ablation has received little attention despite its known predictive value in heart failure outcomes.
Does elevated sST2 predict atrial fibrillation development and recurrence after catheter ablation?
Meta-Analysis (n=14,582)
Does elevated sST2 predict atrial fibrillation development and recurrence after catheter ablation?
The circulating biomarker sST2 is significantly associated with both the development of atrial fibrillation and its recurrence following catheter ablation.
Answers are grounded in this paper and cite their sources.
sST2 may refine post-ablation AF risk stratification; extends meta-analytic support for its predictive role.
Background It is well known that soluble suppression of tumorigenicity 2 (sST2) predicts heart failure outcomes. Little attention has been paid to its use in atrial fibrillation (AF). We investigated whether sST2 is involved in AF formation and recurrence after catheter ablation.Methods A systematic review and meta-analysis study was completed. Until the end of November 2023, the potential articles from Cochrane, OpenMD, PubMed, and ScienceDirect were collected. The assessment of study quality was conducted using the Newcastle-Ottawa scale (NOS). All relevant data from eligible studies were extracted. A random effect model was used for the pooled analysis.Results A total of 14582 participants from 19 studies were involved in this study. The sST2 level was greater in individuals with AF than those with sinus rhythm (standardised mean difference [SMD] = 0.45; 95% confidence interval [CI] = 0.29 to 0.61; p < 0.01). Elevated sST2 levels were correlated with an increased likelihood of developing AF (hazard ratio [HR] = 1.07; 95% CI = 1.00 to 1.14; p = 0.04). A higher sST2 level was found in individuals with recurrent AF (SMD = 0.78; 95% CI = 0.32 to 1.23; p < 0.01). An elevated level of sST2 was related to a greater recurrent AF risk (HR = 1.17; 95% CI = 1.04 to 1.32; p = 0.01).Conclusions The circulating biomarker sST2 has an essential role in AF development. Moreover, sT2 is a significant predictor for recurrent AF after a successful catheter ablation procedure.
No takes yet. Share an insight, caveat, or question.
Waranugraha et al. (2025) conducted a meta-analysis in Atrial fibrillation (n=14,582). Elevated soluble ST2 (sST2) levels vs. Lower sST2 levels / Sinus rhythm was evaluated on Likelihood of developing atrial fibrillation (HR 1.07, 95% CI 1.00 to 1.14, p=0.04). Elevated soluble ST2 levels were associated with an increased likelihood of developing atrial fibrillation and recurrent AF after catheter ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: